PFE — Pfizer Inc.
Is PFE overbought or oversold? Here is the current MarketMoodz read.
Pfizer Inc. (PFE) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Pharmaceuticals) last closed at $28.86. The rating moved from Neutral to Oversold on November 12, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$28.86
- Last changeMoved from Neutral to Oversold on November 12, 2026
- SectorHealthcare
- IndustryPharmaceuticals
See all oversold Healthcare stocks →
AI analysis
Pfizer benefits from a diversified revenue base, strong cash generation and large-cap pharma defensive flows that support share stability and provide optionality from pipeline and partnership activity. Near-term catalysts include earnings season and any late-stage readouts or label expansions. Key strengths are scale, balance-sheet flexibility and established franchise revenues; challenges include legacy product cliffs, payer/regulatory pressure, and competitive dynamics in growth therapeutic classes. Social and filing sentiment in the provided window show no acute negatives, but close monitoring of clinical, regulatory and pricing developments is warranted for directional moves.
Key factors
- Diversified product portfolio including vaccines, oncology, and established branded medicines generating steady cash flow
- Defensive sector flows into large-cap pharma amid macro uncertainty support relative share stability and demand for dividend/quality names
- Healthy balance sheet and free cash generation that enable buybacks, dividends and selective M&A/partnering to bolster specialty franchises
- Earnings-season momentum and potential near-term revenue visibility from recurring vaccines and established franchises
- Pipeline and partnering activity provide upside potential from late-stage assets or label expansions (oncology, specialty care)
- Stable social/filing sentiment with no recent major negative EDGAR items detected in the provided window
Risks
- Ongoing generic erosion and loss of exclusivity on legacy products that can compress revenue over time
- Regulatory and pricing pressure in major markets, including reimbursement changes and payer scrutiny that could reduce margins
- Competition from biotech and other large pharmas, including rapidly expanding obesity/GLP‑1-like franchises that reshape formulary dynamics
- Clinical or regulatory setbacks in key pipeline programs or adverse safety data that could impair near-term sentiment
- Macroeconomic and rate-path uncertainty reducing investor appetite for cyclical upside and impacting valuation multiples
- Legal, product-liability or political/legal interventions on drug pricing or vaccines that could create headline risk
Latest MarketMoodz coverage
- U.S. Asking Prices Post Deepest Annual Drop Since 20172026-07-01
- ADP: June Private Payrolls 98K vs 118K Estimate — Job Growth Cools2026-07-01
- Innovent, Lilly Expand Verzenios Commercialization in China2026-07-01
- Trump: TSMC Arizona Expansion Could Push U.S. to 50% of Chips2026-07-01
- Pfizer's NSCLC ADC misses OS endpoint but shows signal in earlier-line patients2026-06-23
See today's live rating, score and targets
Members see the live hourly rating for PFE — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.